Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280646733> ?p ?o ?g. }
- W4280646733 endingPage "665" @default.
- W4280646733 startingPage "655" @default.
- W4280646733 abstract "The percentage of patients with metastatic non-small cell lung cancer (NSCLC) and melanoma who benefit from anti-programmed cell death protein 1 (anti-PD-1) is low owing to resistance mechanisms. SABR has a role in oligoprogressive disease and can improve responses to anti-PD-1. This multicenter prospective observational study aimed to determine whether concomitant anti-PD-1 and SABR to oligoprogressive sites enhance tumor response in metastatic NSCLC and melanoma.Patients with metastatic NSCLC or melanoma in progression to anti-PD-1 but continuing the same line owing to clinical benefit were referred for palliative SABR. All patients received concomitant pembrolizumab or nivolumab and SABR to 1 to 5 lesions, maintaining anti-PD-1 until further progression, unacceptable toxicity, or medical/patient decision. Objective response rate-complete responses and partial responses-was evaluated during all follow-up according to Response Evaluation Criteria in Solid Tumors 1.1. The abscopal response was evaluated 8 weeks after SABR as a ≥30% reduction in 1 to 2 predefined nonirradiated lesions.Of the 61 patients enrolled, 50 could be analyzed. With a median follow-up of 32.8 months, objective response rate was 42% (30% complete responses and 12% partial responses). Median progression-free survival was 14.2 months (95% confidence interval, 6.9-29 months). Median overall survival since SABR was 37.4 months (95% confidence interval, 22.9 months-not reached). Abscopal response was 65%, evaluated in 40 patients who fulfilled the criteria.Combined anti-PD-1 and SABR in oligoprogressive metastatic NSCLC or melanoma can achieve high rates of response and extend the clinical benefit of immunotherapy by delaying further progression and a new systemic therapy. This approach should be assessed in larger randomized trials." @default.
- W4280646733 created "2022-05-22" @default.
- W4280646733 creator A5002657236 @default.
- W4280646733 creator A5017623334 @default.
- W4280646733 creator A5036068369 @default.
- W4280646733 creator A5043629029 @default.
- W4280646733 creator A5046466073 @default.
- W4280646733 creator A5048883008 @default.
- W4280646733 creator A5055964030 @default.
- W4280646733 creator A5063908957 @default.
- W4280646733 creator A5067592267 @default.
- W4280646733 creator A5077906621 @default.
- W4280646733 creator A5086731525 @default.
- W4280646733 date "2022-11-01" @default.
- W4280646733 modified "2023-09-29" @default.
- W4280646733 title "Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study" @default.
- W4280646733 cites W1964953586 @default.
- W4280646733 cites W1979536922 @default.
- W4280646733 cites W2030227571 @default.
- W4280646733 cites W2039664986 @default.
- W4280646733 cites W2045963664 @default.
- W4280646733 cites W2049553585 @default.
- W4280646733 cites W2080886891 @default.
- W4280646733 cites W2117878645 @default.
- W4280646733 cites W2134471382 @default.
- W4280646733 cites W2137602317 @default.
- W4280646733 cites W2139483106 @default.
- W4280646733 cites W2152897456 @default.
- W4280646733 cites W2156353875 @default.
- W4280646733 cites W2198093519 @default.
- W4280646733 cites W2476838381 @default.
- W4280646733 cites W2521278016 @default.
- W4280646733 cites W2534193912 @default.
- W4280646733 cites W2558219863 @default.
- W4280646733 cites W2578528809 @default.
- W4280646733 cites W2592144107 @default.
- W4280646733 cites W2605380388 @default.
- W4280646733 cites W2624275086 @default.
- W4280646733 cites W2762486219 @default.
- W4280646733 cites W2777859145 @default.
- W4280646733 cites W2796582438 @default.
- W4280646733 cites W2802116219 @default.
- W4280646733 cites W2805354595 @default.
- W4280646733 cites W2808607186 @default.
- W4280646733 cites W2892640821 @default.
- W4280646733 cites W2898394368 @default.
- W4280646733 cites W2899901789 @default.
- W4280646733 cites W2903675605 @default.
- W4280646733 cites W2911314865 @default.
- W4280646733 cites W2939770857 @default.
- W4280646733 cites W2942836156 @default.
- W4280646733 cites W2956407134 @default.
- W4280646733 cites W2958415056 @default.
- W4280646733 cites W2974129609 @default.
- W4280646733 cites W2995626174 @default.
- W4280646733 cites W3005408074 @default.
- W4280646733 cites W3013243565 @default.
- W4280646733 cites W3019546741 @default.
- W4280646733 cites W3031153849 @default.
- W4280646733 cites W3047412046 @default.
- W4280646733 cites W3092159910 @default.
- W4280646733 cites W3093708469 @default.
- W4280646733 cites W4206362366 @default.
- W4280646733 cites W4292528167 @default.
- W4280646733 doi "https://doi.org/10.1016/j.ijrobp.2022.05.013" @default.
- W4280646733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35595158" @default.
- W4280646733 hasPublicationYear "2022" @default.
- W4280646733 type Work @default.
- W4280646733 citedByCount "12" @default.
- W4280646733 countsByYear W42806467332022 @default.
- W4280646733 countsByYear W42806467332023 @default.
- W4280646733 crossrefType "journal-article" @default.
- W4280646733 hasAuthorship W4280646733A5002657236 @default.
- W4280646733 hasAuthorship W4280646733A5017623334 @default.
- W4280646733 hasAuthorship W4280646733A5036068369 @default.
- W4280646733 hasAuthorship W4280646733A5043629029 @default.
- W4280646733 hasAuthorship W4280646733A5046466073 @default.
- W4280646733 hasAuthorship W4280646733A5048883008 @default.
- W4280646733 hasAuthorship W4280646733A5055964030 @default.
- W4280646733 hasAuthorship W4280646733A5063908957 @default.
- W4280646733 hasAuthorship W4280646733A5067592267 @default.
- W4280646733 hasAuthorship W4280646733A5077906621 @default.
- W4280646733 hasAuthorship W4280646733A5086731525 @default.
- W4280646733 hasConcept C106159729 @default.
- W4280646733 hasConcept C121608353 @default.
- W4280646733 hasConcept C126322002 @default.
- W4280646733 hasConcept C143998085 @default.
- W4280646733 hasConcept C162324750 @default.
- W4280646733 hasConcept C187625094 @default.
- W4280646733 hasConcept C2776256026 @default.
- W4280646733 hasConcept C2777658100 @default.
- W4280646733 hasConcept C2777701055 @default.
- W4280646733 hasConcept C2779384505 @default.
- W4280646733 hasConcept C2780030458 @default.
- W4280646733 hasConcept C2780057760 @default.
- W4280646733 hasConcept C502942594 @default.
- W4280646733 hasConcept C71924100 @default.
- W4280646733 hasConcept C85393063 @default.